Home > Newsletters > The QMN Weekly Bulletin > FDA Warning to Hospira Infusion Plant May Hint at Broader Problems
The QMN Weekly Bulletin
Sept. 21, 2012 | Vol. 4 No. 38
FDA Warning to Hospira Infusion Plant May Hint at Broader Problems
An FDA warning letter issued to Hospira’s infusion pump plant in Costa Rica may be emblematic of broader companywide manufacturing issues, analysts say.
The five-observation letter, dated Aug. 22, was sent to Hospira’s Lake Forest, Ill., headquarters following an April 16-19 inspection of the La Aurora de Heredia, Costa Rica, facility. The company disclosed the warning in an Aug. 23 SEC filing, which noted that the site is responsible for manufacturing most of Hospira’s infusion products.
Hospira has been warned by the FDA in the past about manufacturing issues affecting its injectables business. And in 2009, the company received a warning letter for distributing infusion pumps known to have defective power cords.
The new warning “suggests Hospira’s manufacturing issues may be more systemic than investors realize,” analyst Shibani Malhotra of RBC Capital Markets wrote in a research note.
Could different answers during Hospira’s inspection interview have changed the outcome?
Surviving an FDA Inspection Interview is FDAnews’ time-tested solution to one of the biggest inspection prep challenges any company faces, and will lead your employees through scenarios that can take an inspection off-track.
This instructional guide and DVD creates a powerful, hour-long training event that shows employees the types of questions and tactics they’ll face during inspection and gives them the confidence to respond correctly. Don’t delay, order this critical educational tool today!
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.